All In Biotech

Drug Trial Radar · NCT06414460

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

Apr 25, 2025

Primary completion

Mar 31, 2028

Study completion Mar 31, 2029

Sponsor

Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

  • ISM3412Drug

    ISM3412 will be administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT) eventsTime frame: 31 days
  2. Incidence and severity of adverse events (AEs)Time frame: Approximately 30 months
  3. Recommended phase 2 dose (RP2D)Time frame: Approximately 30 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • Smilow Cancer Hospital at Yale New Haven Breast Center

    New Haven, Connecticut · Recruiting

  • Community Cancer Center North

    Indianapolis, Indiana · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen university cancer center

    Guangzhou, Guangdong, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai Gobroad Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.